Evidence map›Paper›PMID 37577338›Full record

ArticleInternational cancer conference journal2023

Intrahepatic cholangiocarcinoma with FGFR2 fusion gene positive that responded to pemigatinib and caused hypophosphatemia.

Yoshinori Kikuchi, Kazuhisa Yamaguchi, Ryo Shimizu, Yuu Matsumoto, Yasuko Kurose, Naoki Okano, Yuichirou Otsuka, Kazutoshi Shibuya, Takahisa Matsuda, Hideaki Shimada

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International cancer conference journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 72% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yoshinori KikuchiDepartment of Clinical Oncology, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541 Japan.ORCID 0000-0001-6070-6927
Kazuhisa YamaguchiDivision of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), Toho University, Tokyo, Japan.
Ryo ShimizuDivision of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), Toho University, Tokyo, Japan.
Yuu MatsumotoDivision of General and Gastroenterological Surgery, Department of Surgery (Omori), Toho University, Tokyo, Japan.
Yasuko KuroseDepartment of Surgical Pathology (Omori), Toho University, Tokyo, Japan.
Naoki OkanoDivision of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), Toho University, Tokyo, Japan.
Yuichirou OtsukaDivision of General and Gastroenterological Surgery, Department of Surgery (Omori), Toho University, Tokyo, Japan.
Kazutoshi ShibuyaDepartment of Surgical Pathology (Omori), Toho University, Tokyo, Japan.
Takahisa MatsudaDivision of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), Toho University, Tokyo, Japan.
Hideaki ShimadaDepartment of Clinical Oncology, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541 Japan.
Toho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intrahepatic cholangiocarcinoma is a condition with a poor prognosis. Traditionally, there was no cure unless important drugs such as gemcitabine, cisplatin, and tegafur/gimeracil/uracil potassium showed efficacy. Pemigatinib has recently become accessible for the treatment of intrahepatic cholangiocarcinoma with FGFR2 fusion or rearrangement gene abnormalities. Hyperphosphatemia is typically linked to pemigatinib. In the current case, pemigatinib was used to effectively treat a 48-year-old woman, and hypophosphatemia was observed. Patients with intrahepatic cholangiocarcinoma should undergo aggressive cancer multigene panel testing as well as careful monitoring of serum phosphorus levels.

Indexed as

ChemotherapyFibroblast growth factor receptor 2 fusion geneIntrahepatic cholangiocarcinomaPemigatinib

Identifiers

PMID37577338
PMCPMC10421826
OpenAlexW4382940369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.